Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: NASDAQ GM
  • Sector: Consumer, Non-cyclical
  • Industry: Biotechnology
  • Sub-Industry: Medical-Biomedical/Gene

PATH:US

3.1700 USD 0.0600 1.93%

As of 20:10:00 ET on 05/24/2013.

Company Profile for NuPathe Inc (PATH)

NuPathe Inc. develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. The Company offers various medicines for migraines, Parkinson's, schizophrenia, and other cognitive disorders.

Contact Information

NuPathe Inc

227 Washington Street
Suite 200
Conshohocken, PA 19428
United States
Phone: 1-484-567-0130
Fax: 1-484-567-0136

Key Executives for NuPathe Inc (PATH)

Wayne P YetterChairmanArmando AnidoChief Executive Officer
Terri B SebreePresident/Co-FounderKeith Alan GoldanVP/CFO
Gerald W McLaughlin "Jerry"VP/Chief Commercial OfficerMichael F MarinoVP/Secretary/General Counsel

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil